98 related articles for article (PubMed ID: 27267848)
1. Role of mTOR Inhibitors in Growth Hormone-Producing Pituitary Adenomas Harboring Different FGFR4 Genotypes.
Jalali S; Monsalves E; Tateno T; Zadeh G
Endocrinology; 2016 Sep; 157(9):3577-87. PubMed ID: 27267848
[TBL] [Abstract][Full Text] [Related]
2. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.
Serra S; Zheng L; Hassan M; Phan AT; Woodhouse LJ; Yao JC; Ezzat S; Asa SL
Cancer Res; 2012 Nov; 72(22):5683-91. PubMed ID: 22986737
[TBL] [Abstract][Full Text] [Related]
3. The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis.
Tateno T; Asa SL; Zheng L; Mayr T; Ullrich A; Ezzat S
PLoS Genet; 2011 Dec; 7(12):e1002400. PubMed ID: 22174695
[TBL] [Abstract][Full Text] [Related]
4. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas.
Morita K; Takano K; Yasufuku-Takano J; Yamada S; Teramoto A; Takei M; Osamura RY; Sano T; Fujita T
Clin Endocrinol (Oxf); 2008 Mar; 68(3):435-41. PubMed ID: 18070145
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
6. Specific inhibition of mTOR pathway induces anti-proliferative effect and decreases the hormone secretion in cultured pituitary adenoma cells.
Xie R; He WQ; Shen M; Shou XF; Wang YF; Bao WM; Zhao Y
J Neurooncol; 2015 Oct; 125(1):79-89. PubMed ID: 26297046
[TBL] [Abstract][Full Text] [Related]
7. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
[TBL] [Abstract][Full Text] [Related]
9. FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors.
Ezzat S; Wang R; Pintilie M; Asa SL
Oncotarget; 2017 Jan; 8(2):3481-3494. PubMed ID: 27966451
[TBL] [Abstract][Full Text] [Related]
10. mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features.
Sajjad EA; Zieliński G; Maksymowicz M; Hutnik Ł; Bednarczuk T; Włodarski P
Endocr Pathol; 2013 Mar; 24(1):11-9. PubMed ID: 23296986
[TBL] [Abstract][Full Text] [Related]
11. PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line.
Di Pasquale C; Gentilin E; Falletta S; Bellio M; Buratto M; Degli Uberti E; Chiara Zatelli M
Endocrine; 2018 May; 60(2):308-316. PubMed ID: 29080043
[TBL] [Abstract][Full Text] [Related]
12. In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.
Cuny T; Zeiller C; Bidlingmaier M; Défilles C; Roche C; Blanchard MP; Theodoropoulou M; Graillon T; Pertuit M; Figarella-Branger D; Enjalbert A; Brue T; Barlier A
Endocr Relat Cancer; 2016 Jul; 23(7):509-19. PubMed ID: 27267119
[TBL] [Abstract][Full Text] [Related]
13. Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas.
Zhang D; Way JS; Zhang X; Sergey M; Bergsneider M; Wang MB; Yong WH; Heaney AP
J Clin Endocrinol Metab; 2019 Jun; 104(6):1929-1936. PubMed ID: 30624667
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors.
Chen Y; Gao H; Liu Q; Xie W; Li B; Cheng S; Guo J; Fang Q; Zhu H; Wang Z; Wang J; Li C; Zhang Y
Aging (Albany NY); 2020 Dec; 13(1):1422-1439. PubMed ID: 33472171
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Hyytiäinen M; Kilpinen S; Kallioniemi O; Ingvarsen S; Engelholm LH; Taipale J; Alitalo K; Keski-Oja J; Lehti K
Cancer Res; 2010 Oct; 70(20):7851-61. PubMed ID: 20876804
[TBL] [Abstract][Full Text] [Related]
16. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
17. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.
Ezzat S; Zheng L; Winer D; Asa SL
Mol Endocrinol; 2006 Nov; 20(11):2965-75. PubMed ID: 16857743
[TBL] [Abstract][Full Text] [Related]
18. Increased milk protein synthesis in response to exogenous growth hormone is associated with changes in mechanistic (mammalian) target of rapamycin (mTOR)C1-dependent and independent cell signaling.
Sciascia Q; Pacheco D; McCoard SA
J Dairy Sci; 2013 Apr; 96(4):2327-2338. PubMed ID: 23462168
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376
[TBL] [Abstract][Full Text] [Related]
20. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]